Last reviewed · How we verify
NCT06557525
Focused Research On Neurofeedback Therapy In Eradicating Depression (FRONTIER)
Phase 1, PHASE2 trial testing Neurofeedback in Depression in 30 participants. Currently enrolling.
30 September 2024
Quick facts
| Lead sponsor | UNB Sumiyoshi Jinja Mae Clinic |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 20 November 2023 |
| Primary completion | 30 September 2024 |
| Estimated completion | 31 March 2025 |
| Sites | 1 location across Japan |
Drugs / interventions tested
- Neurofeedback
Conditions studied
- Depression — all drugs for Depression →
Sponsor
UNB Sumiyoshi Jinja Mae Clinic
Who can join
18 and older, any sex, with Depression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an exploratory study to test the efficacy of a novel EEG neurofeedback method in depressed patients. The investigators will measure the change in depressive symptoms before and after the intervention of the novel EEG neurofeedback method using the Depression Rating Scale (primary endpoint). In addition, The investigators will measure the changes in brain activity before and after the intervention using fMRI, and compare the changes in depressive symptoms over the treatment period (secondary endpoint).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06557525
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Neurofeedback
Trials testing the same drug.
- NCT07356661 — Evaluation of the Efficacy of Neurofeedback Technique Based on EEG Desynchronization in Epileptic Patients · NA · not yet recruiting
- NCT06587919 — Improving Dysregulated Neural Networks With EEG-neurofeedback · NA · enrolling by invitation
- NCT06240299 — Neurofeedback for Nociplastic Pain in Rheumatoid Arthritis (NECTAR) · NA · recruiting
- NCT06188910 — Neurofeedback and Nomophobia in Young Adults · NA · completed
- NCT05592600 — Investigating Electroencephalographic Predictors of Default Mode Network Anticorrelation in Healthy Adults · NA · completed
Other recruiting trials for Depression
Currently open trials in the same condition.
- NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
- NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression · EARLY_PHASE1 · recruiting
- NCT07517549 — Sexual Health Education During Pregnancy · NA · recruiting
- NCT06408246 — ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression · Phase 2 · recruiting
- NCT07449676 — Effects of an Innovative TCM-based Tui Jing Therapy on Psychological and Neurophysiological Functions in Depression · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06557525 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by UNB Sumiyoshi Jinja Mae Clinic
- Last refreshed: 16 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06557525.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing